Replimune Group, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
REPL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 Unicorn Park, Woburn, Massachusetts

Insiders trading volume in the past year

Replimune Group, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Omega Fund IV, L.P. 10%+ Owner $103 M Mar 14, 2022
Robert Coffin Director $11.8 M -$74.2 K -0.63% May 16, 2024
Philip Astley-Sparke Executive Chairman, Director $9.62 M -$245 K -2.49% May 16, 2024
Colin Love Chief Operating Officer $5.03 M -$114 K -2.22% May 16, 2024
Pamela Esposito Chief Business Officer $2.88 M -$945 K -24.7% Sep 11, 2023
Tanya Lewis Chief Dev. Op. Officer $1.48 M Jun 13, 2023
Jean Franchi Chief Financial Officer $1.41 M May 16, 2023
Sushil Patel Chief Executive Officer, Director $1.37 M -$131 K -8.7% May 16, 2024
Emily Luisa Hill Chief Financial Officer $1.2 M Apr 1, 2024
Konstantinos Xynos Chief Medical Officer $878 K -$240 K -21.5% Jun 7, 2024
Christopher Sarchi Chief Commercial Officer $597 K -$71.7 K -10.7% May 16, 2024
Andrew Schwendenman Chief Accounting Officer $247 K -$14.9 K -5.67% May 16, 2024
Kapil Dhingra Director Apr 1, 2024
Paolo Pucci Director Apr 1, 2024
Christy J. Oliger Director Apr 1, 2024
Jason P. Rhodes Director Apr 1, 2022
Hugo Alexander Slootweg Director Apr 1, 2023
Dieter Weinand Director Apr 1, 2024
Veleka Peeples-Dyer Director Apr 1, 2024
Joseph P. Slattery Director Apr 1, 2024
Hyam Levitsky Director Apr 1, 2024

Recent Insider Transactions by Companies or Individuals for Replimune Group, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership